Search Results
Results found for "COVID-19"
Posts (128)
- Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19...
November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID -19 and Other Antibody Therapeutics for Difficult to Treat Diseases "Nov 15, 2021 -- Executive Leadership
- First in Human: Early-stage COVID therapies hold promise against omicron variant
December 2021 "Early-stage studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants
- Platelets in the NETworks interweaving inflammation and thrombosis
In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than ever, as a majority of COVID-19 patients display thrombi in the lung capillaries and other vascular
Other Pages (66)
- Session IX / Technology capsule: Light on aGPCR signaling and function | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID -19 vaccines, is emerging as a promising method for antibody discovery.
- Eleonora Comeo | Dr. GPCR Ecosystem
We also touched on how COVID-19 affected her Ph.D. work.
- Fresh, Fresh, GPCR News ❇ Feb 17 - 23, 2025 | Dr. GPCR Ecosystem
GPCR research, developing biosensors for G protein activity, networking, mentorship, PhD resilience, COVID -19 challenges, and his aspiration to transition into biotechnology investment opportunities. Next Call for GPCR Papers Special Issue on Adhesion GPCRs GPCR Events, Meetings, and Webinars March 19
